BCL2L1 and breast carcinoma: As examples, miR-155 modulates breast cancer cell sensitivity to doxorubicin, paclitaxel and etoposide [5], miR-148a decreases paclitaxel resistance of prostate cancer cells [14], miR-125b confers paclitaxel resistance in breast cancer cells by decreasing Bcl-2 expression [15], and the let-7 family of miRNAs inhibits Bcl-xl expression and potentiates sorafenib-induced apoptosis in human hepatocarcinoma [16].